Sun Pharma receives USFDA nod ophthalmic solution used to treat dry eye disease

Dry Eye Disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated, Abhay Gandhi, CEO, North America, Sun Pharma.

Sun Pharma receives USFDA nod ophthalmic solution used to treat dry eye disease
"The the US Food and Drug Administration (USFDA) approval of CEQUA represents a long-awaited dry eye treatment option and is an important milestone in the development of Sun's Ophthalmics business," Representational Image, Image source: Reuters
Written By: PTI
Updated: Thu, Aug 16, 2018
02:02 pm
New Delhi, PTI
RELATED NEWS
Coronavirus impact on investor wealth: Rs 19.49 lakh cr wiped out in 4 days of share market mayhem Coronavirus impact on investor wealth: Rs 19.49 lakh cr wiped out in 4 days of share market mayhem
Share market: Sensex tanks over 1,100 points, Nifty 335 over Coronavirus fears Share market: Sensex tanks over 1,100 points, Nifty 335 over Coronavirus fears
Share market today: Sensex drops over 200 pts; Nifty near 11,600 Share market today: Sensex drops over 200 pts; Nifty near 11,600
What are penny stocks and 5 reasons why you shouldn't buy them - Explained What are penny stocks and 5 reasons why you shouldn't buy them - Explained

Sun Pharma has received approval from the US health regulator for CEQUA (cyclosporine ophthalmic solution), used to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dry Eye Disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated, Abhay Gandhi, CEO, North America, Sun Pharma.

"The the US Food and Drug Administration (USFDA) approval of CEQUA represents a long-awaited dry eye treatment option and is an important milestone in the development of Sun's Ophthalmics business," said he added.

"CEQUA (cyclosporine ophthalmic solution) 0.09 per cent, for topical ophthalmic use will be commercialised in the US by Sun Ophthalmics, the branded ophthalmics division of Sun Pharma's wholly owned subsidiary," Sun Pharma said in a BSE filing.

CEQUA is dosed twice daily and will be available as a single-use vial.

Watch Zee Business video here:

 

Shares of Sun Pharma were trading 2.25 per cent higher at Rs 615.20 apiece on BSE.

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.